Clinical Trial Update: Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures [Phase 3]

View source ↗

Summary

This update reports the completion of a Phase 3 safety and pharmacokinetic study of cenobamate (YKP3089) as adjunctive therapy for partial onset seizures. Resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial-onset Seizures

Drugs mentioned

• Xcopri (cenobamate)

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Partial Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2024-05-14